Asset Details

MbrlCatalogueTitleDetail

Do you wish to reserve the book?

Dasatinib–Blinatumomab for Ph-Positive Acute Lymphoblastic Leukemia in Adults

by Bassan, Renato , Guarini, Anna , Lunghi, Monia , Piciocchi, Alfonso , Fracchiolla, Nicola , Vignetti, Marco , Elia, Loredana , Rambaldi, Alessandro , Viero, Piera , De Propris, Maria-Stefania , Foà, Robin , Ferrara, Felicetto , Mancino, Alessandra , Fabbiano, Francesco , Canichella, Martina , Di Bartolomeo, Paolo , Vitale, Antonella , Puzzolo, Maria-Cristina , Bonifacio, Massimiliano , Chiaretti, Sabina

in Acute lymphoblastic leukemia / Adult / Aged / Aged, 80 and over / Allografts / Antibodies, Bispecific - administration & dosage / Antineoplastic Combined Chemotherapy Protocols - adverse effects / Antineoplastic Combined Chemotherapy Protocols - therapeutic use / Bone marrow / Cell death / Chemotherapy / Confidence intervals / Consolidation Chemotherapy / Dasatinib - administration & dosage / Design / Female / Gene expression / Glucocorticoids / Hematopoietic Stem Cell Transplantation - adverse effects / Humans / Hypotheses / Induction Chemotherapy / Induction therapy / Kinases / Leukemia / Lymphatic leukemia / Lymphocytes / Male / Medical prognosis / Middle Aged / Minimal residual disease / Monoclonal antibodies / Mutation / Pax5 protein / Philadelphia Chromosome / Precursor Cell Lymphoblastic Leukemia-Lymphoma - drug therapy / Precursor Cell Lymphoblastic Leukemia-Lymphoma - genetics / Precursor Cell Lymphoblastic Leukemia-Lymphoma - mortality / Precursor Cell Lymphoblastic Leukemia-Lymphoma - therapy / Protein-tyrosine kinase / Proteins / Remission / Remission Induction / Survival Analysis / Targeted cancer therapy / Transplantation / Treatment Outcome

2020

Yes Please

Hey, we have placed the reservation for you!

By the way, why not check out events that you can attend while you pick your title.

Oops! Something went wrong.

Looks like we were not able to place the reservation. Kindly try again later.

Are you sure you want to remove the book from the shelf?

Dasatinib–Blinatumomab for Ph-Positive Acute Lymphoblastic Leukemia in Adults

2020

Confirm

Do you wish to request the book?

Dasatinib–Blinatumomab for Ph-Positive Acute Lymphoblastic Leukemia in Adults

2020

Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy

How would you like to get it?

Submit

We have requested the book for you!

Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.

Oops! Something went wrong.

Looks like we were not able to place your request. Kindly try again later.

Journal Article

Dasatinib–Blinatumomab for Ph-Positive Acute Lymphoblastic Leukemia in Adults

Bassan, Renato,

Guarini, Anna,

Lunghi, Monia,

Piciocchi, Alfonso,

Fracchiolla, Nicola,

Vignetti, Marco,

Elia, Loredana,

Rambaldi, Alessandro,

Viero, Piera,

De Propris, Maria-Stefania,

Foà, Robin,

Ferrara, Felicetto,

Mancino, Alessandra,

Fabbiano, Francesco,

Canichella, Martina,

Di Bartolomeo, Paolo,

Vitale, Antonella,

Puzzolo, Maria-Cristina,

Bonifacio, Massimiliano,

Chiaretti, Sabina

2020

Overview

In patients who have acute lymphoblastic leukemia with tumor cells that bear the Philadelphia chromosome, traditional therapy is not very effective. The use of the ABL kinase inhibitor dasatinib to achieve remission, followed by the bifunctional antibody blinatumomab (which has both anti-CD3 and anti-CD19 specificity as maintenance therapy), led to complete remission in 98% of the patients.

Share this book

Add to My Shelf

Publisher

Massachusetts Medical Society

Subject

Acute lymphoblastic leukemia

/ Adult

/ Aged

/ Aged, 80 and over

/ Allografts

/ Antibodies, Bispecific - administration & dosage

/ Antineoplastic Combined Chemotherapy Protocols - adverse effects